###-----------------------------------------------------------------------------
### Check for the required packages and set options and variables
###-----------------------------------------------------------------------------
if (!('ufs' %in% row.names(installed.packages()))) {
if (!(packageVersion('ufs') >= "0.4")) {
stop("You need to have R package `ufs` installed in at least ",
"version 0.4. If that version is not yet on CRAN, you can ",
"install it from GitLab with the `remotes` package and command:\n\n",
"remotes::install_gitlab('r-packages/ufs');");
}
}
producePlots <- TRUE;
produceConfidencePlots <- TRUE;
quiet = TRUE;
installPkgs = FALSE;
### Check for required packages
ufs::checkPkgs("DiagrammeR", install=installPkgs); ### Imported by `mdmcda`
ufs::checkPkgs("DiagrammeRsvg", install=installPkgs); ### Imported by `mdmcda`
ufs::checkPkgs("ggplot2", install=installPkgs); ### Imported by `mdmcda`
ufs::checkPkgs("ggtext", install=installPkgs); ### Imported by `mdmcda`
ufs::checkPkgs("justifier", install=installPkgs); ### Imported by `mdmcda`
ufs::checkPkgs("knitr", install=installPkgs); ### Imported by `mdmcda`
ufs::checkPkgs("kableExtra", install=installPkgs); ### Imported by `mdmcda`
ufs::checkPkgs("openxlsx", install=installPkgs); ### Imported by `mdmcda`
ufs::checkPkgs("yum", install=installPkgs); ### Imported by `mdmcda`
ufs::checkPkgs("tidyr", install=installPkgs); ### Used once for pivot_wider
ufs::checkPkgs("patchwork", install=installPkgs); ### Combining ggplots
ufs::checkPkgs("sessioninfo", install=installPkgs); ### For reporting session information
### Update `mdmcda` from GitLab; use development branch
ufs::quietGitLabUpdate("r-packages/mdmcda@dev", quiet=quiet);
if (knitr::is_html_output()) {
knitr::opts_chunk$set(echo=TRUE);
} else {
knitr::opts_chunk$set(echo=FALSE);
}
options(knitr.kable.NA = '');
knitr::opts_chunk$set(dev="png",
dev.args=list(type="cairo"),
dpi=150,
comment="");
ufs::opts$ez$figSize(size = "a4",
fontSizeMultiplier = 1.3);
mdmcda::opts$ez$figSize(size = "a4",
fontSizeMultiplier = 1.3);
ufs::opts$set(ggSaveDPI = 150);
mdmcda::opts$set(ggSaveDPI = 150);
### Set regular expressions for extracting decision and criterion
### identifiers from the performance subtable filenames
mdmcda::opts$set(
performanceTable_decisionRegex =
c("performance_subtable_for_(.*)_on_.*_by_all\\.xlsx$",
"\\1")
);
mdmcda::opts$set(
performanceTable_criterionRegex =
c("performance_subtable_for_.*_on_(.*)_by_all\\.xlsx$",
"\\1")
);
ggBaseSize <-
mdmcda::opts$get('ggBaseSize');
### Set variable names
scorerId <- "all";
weightProfileName <- "meanWeights"
weightedEstimateName <- paste0(weightProfileName, "_weighted_estimate");
tempWeightedEstimateName <- paste0(scorerId, "_", weightedEstimateName);
### Set path with files
currentDir <- here::here();
dataPath <- file.path(currentDir, "data");
workingPath <- file.path(currentDir, "results");
scoredPST_path <- file.path(dataPath, "scored-PSTs");
### Set filenames
criteriaFile <-
file.path(dataPath,
"mdma-policy-mdmcda-fullCriteriaDf.xlsx");
postSetsFile <-
file.path(dataPath,
"postsets--(adjustments-after-collective-scoring-days).xlsx");
scenariosFile <-
file.path(dataPath,
"mdma-scenario-definitions.xlsx");
weightsFile <-
file.path(dataPath,
"mdma-criteria-weights.xlsx");
### Tell ufs::knitAndSave to always 'cat' the knitr chunk
options(ufs.knitAndSave.catPlot = TRUE);
### Set automatic figure numbering
ufs::setFigCapNumbering();
This reproducible report documents the analyses done for the MDMA Policy Think Tank that was active in the Netherlands in 2019-2020 (see the Background tab for more details). This document loads the produced data and computes the results. The most recent version of this document is hosted at https://denktank.gitlab.io/mdma-policy-mdmcda, the corresponding Git repository is at https://gitlab.com/denktank/mdma-policy-mdmcda, the Open Science Framework project for this repository is https://osf.io/h58r6/, and as of November the 13th, a preprint will be available at https://doi.org/10.31219/osf.io/txy5z.
This document is organised in the tabs above:
There is an online app at https://mdmapolicy.com/app where you can specify your own policy model and weights for the outcomes. https://mdmapolicy.com (an alias of https://mdmabeleid.nl) is a website about this project where, as of the 13th of November, a Dutch-language report will become available.
mdmcda
R packageThe Think Tank used Multi Decision Multi Criteria Decision Analysis, which is an adaption of the MCDA procedure. This document and all analyses reported here use the mdmcda
R package, available through https://r-packages.gitlab.io/mdmcda. Note that it is still under development, which is why this repository has been frozen as a registration in the Open Science Framework project at https://osf.io/h58r6/. If you run into any issues with reproducing these analyses, or if you would like to use this R package to conduct an MDMCDA in your own country, you can contact Gjalt-Jorn Peters (the package developer, who also wrote this reproducible document) through Twitter or email.
Discussions about drug policy often polarize. Often, individuals’ morals, prejudices and emotions come to drive the discussion rather than theory- and evidence-based argument and trying to find the best solution.
To attempt to identify the best way forward without the process being derailed by idealistic and emotional arguments, formal decision-making instruments have been employed. A famous example is the application of Multi Criteria Decision Analysis to rank drug harms in the UK (Nutt, King & Phillips, 2010). This same approach can be used to not only look at drug harms, but also at the effects different drug policies have on such harms.
Røgeberg et al. (2017) did exactly this. They compared four regulatory regimes (absolute prohibition, decriminalisation, state control and free market) and used Multi Criteria Decision Analysis (MCDA) to compare their estimated effects on 27 criteria (e.g. “Reduce user harms”, “Enable medical use”, “Promote family cohesion”, “Reduce acquisitive crime”, and “Reduce economic sosts”) for alcohol and cannabis. For both drugs, state control emerged as the optimal regime.
However, a drawback of this approach is that in the process of estimating each regulatory regime’s performance on the criteria, the experts are aware of how the pattern of estimates impacts the relative performances of each regulatory model. This leaves the process relatively open to pre-existing biases.
In the Dutch think tank process, we aimed to eliminate such biases as much as possible. To do this, an R package was developed that implements Multi Decision Multi Criteria Decision Analysis (MDMCDA). The Method tab contains a description of how this relates to MCDA. In short: the scenarios (called “regulatory regimes” by Røgeberg et a. (2017) and “policy models” in the current exercise) are not predefined, but only defined afterwards. We split up the process in an “objective phase” and a “subjective phase”.
In the “objective phase”, the first two steps were to establish:
The next step was to estimate the effects of all alternatives within all decisions (all policy options within all instruments) on all criteria (outcomes). For example, if selling MDMA would require a license, how would that impact the prevalence of MDMA use, health damage, MDMA-related organised crime, and damage to the environment?
Once all these effects had been estimated, that concluded the more objective expert input part of the exercise.
The next two steps are mostly informed by personal or political preference and so are more subjective. These two steps are specifying the following two things.
Once these have been specified, it is possible to weigh all the estimates using the specified weights, and then compute the total scores for all scenarios given the selected alternatives that comprise them.
This approach reduces bias because the experts estimate the effects of single alternatives (options) within decisions (instruments) on single criteria each time. Because at that point, the scenarios (policy models) have not yet been defined, and the criteria have not yet been weighted, it is not possible to change these estimates to make a given scenario “win”.
An second benefit is that defining the scenarios and specifycing the weights becomes independent of the estimates. It is wasy to change scenarios or weights afterwards and again compute how each scenario scores. In addition, it is possible to compose a scenario out of the highest-scoring alternative (option) within each decision (policy instrument), as well as compute the worst-scoring scenario.
A third characteristic of MDMCDA is instead of so-called “swing weighting”, global weighting is used (see the Method tab for details and rationale). This can be soon both as a disadvantage and an advantage, but one specific benefit is that this disentangles the “importance” and “impact” dimensions, which are combined in one weight when applying swing weighting. The impact is expressed in the estimates set in phase 1, whereas the importance is determined in phase 2.
cat('This document is the technical report with all results. It contains all the R code used to generate these results. The R code can be expanded by clicking the "Code" button that sometimes appears at the right-hand side of the page, such as just above this paragraph, which will show the `cat` command used to print this paragraph.');
This document is the technical report with all results. It contains all the R code used to generate these results. The R code can be expanded by clicking the “Code” button that sometimes appears at the right-hand side of the page, such as just above this paragraph, which will show the cat
command used to print this paragraph.
To view underlying data or the R scripts themselves, check out the repository at https://gitlab.com/denktank/mdma-policy-mdmcda. This file and the other repository contents are frozen when a manuscript is submitted. These frozen public registrations are available at out Open Science Framework repository at https://osf.io/h58r6/.
In regular Multi Criteria Decision Analysis (MCDA), a number of alternatives are crossed with a number of criteria as means to select the optimal alternative. The table obtained by crossing all alternatives with all criteria is called a performance table, and each cell contains an estimate. By weighting the criteria in terms of their importance the optimal alternative can be computed. Often, this weighting not only weighs each criterion’s importance, but simultaneously the relative magnitude of the impact the alternatives can have on each criterion, in which case the weighting is called swing weighting. Swing weighting also serves the purpose of calibrating differences in metric between criteria.
However, regarding substance policy, achieving consensus on a manageable set of alternatives, as well as on the weights to use, is challenging and perhaps impossible. For example, experts in legal systems and policing might define a “prohibition” policy very differently from experts in health and prevention. Similarly, experts in economy and tax policy might define a “free market” system very differently than experts in policing and prevention. Similar variation exists is preferred weighting: for example, criteria relating to crime and health may be weight differently by health professionals than by police officers.
This presents a problem for MCDA, which requires predefined alternatives. To respect these different viewpoints, a specific application of the MCDA procedure was used that works for multiple decisions as well as multiple criteria (Multi Decision Multi Criteria Decision Analysis, MDMCDA). MDMCDA enables establishing both the alternatives and the weights after the estimates in the performance table have been produced. In order to do this, it sacrifices the elegance of swing weighting. Specifically, MDMCDA assumes that each alternative can be broken down into separate decisions that each have “sub-alternatives” of their own.
For example, a “prohibiton policy” alternative may differ from a “free market” alternative in the decision whether sale to consumers is legal or not, as well as in the decision whether quality standards are defined. Each of these two decisions comprises a number of sub-alternatives: for example, sale to consumers can be legal, illegal, or only legal with a license; and quality standards can either be defined by a governmental body or not. A “prohibition policy” may consist of the alternatives that sale to consumers is illegal and no quality standards are defined; and a “free market” alternative may consist of the alternatives that sale to consumers is legal and quality standards are defined.
Once all relevant decisions and all relevant “sub-alternatives” for each decision have been identified, each alternative (in the MCDA meaning of the word) can be defined in terms of which “sub-alternative” is selected within each decision. However, defining the alternatives is now no longer a precondition for producing the estimates in the performance tables (i.e. the estimates of the effects on each criterion). These estimates can now be produced on the level of the “sub-alternatives”. In other words, Multi Decision Multi Criterion Decision Analysis breaks down the MCDA procedure into a set of related sub-MCDA procedures, that are aggregated again once all performance sub-tables have been produced.
For example, in the example introduced above, the effects of whether sale to consumers is legal, illegal, or only legal with a license would be estimated for each criterion; and the effects of whether quality standards exist or not would also be estimated for each criterion. If the criteria would be, for example, “health” and “crime”, this would mean that for the first decision (legal status of sale to consumers), three estimates would be produced for the effects on health, and three for the effects on crime. For the second decision (whether quality standards exist), two estimates would be produced for the effects on health, and two for the effects on crime.
In total, therefore, ten estimates would be produced, in two performance sub-tables (each decision has its own performance sub-table). In a traditional MCDA, only four estimates would be produced: two alternatives (prohibition versus free market) crossed with two criteria (health and crime). As will be clear, when applying DMCDA as opposed to MCDA, the number of estimates to be produced is much higher. This is a disadvantage in terms of required effort, but is an advantage in terms of how complex estimating the effect on each criterion is. Breaking down each alternative into decisions and sub-alternatives means estimating the effects on each criterion requires less mental aggregation of component effects.
Often, criteria in an MCDA can be organized hierarchically. For example, the criterion “health” may in fact be a cluster of criteria “acute risks” and “long-term neurotoxicity”, and the criterion “crime” may be a cluster of criteria “organized crime” and “petty crime”. In MCDA, the full performance table is in practice split up by criterion cluster (i.e. by cluster of columns). For example, first the effects of each alternative on both criteria in the “health” cluster would be scored, and then the effects of each alternative on both criteria in the “crime” cluster.
Since swing weighting is performed for the effects on all alternatives on each criterion, this splitting up of the performance table by clusters of columns does not pose any problems. In MDMCDA, however, the performance table is also by each decision. Since in MDMCDA, the full performance table does not consist of alternatives crossed with criteria, but instead of decisions and their sub-alternatives crossed with criteria, the resulting performance table has many more rows than the performance table in conventional MCDA. During estimating each sub-alternative’s effect on the criteria in each cluster, therefore, the full performance table is also split by decision. This means the full performance table can be viewed as a grid of performance subtables: one for each criteria cluster-decision combination.
In our example, with two clusters (crime and health) that each consist of two criteria (organized and petty crime; and acute and long-term risk), and two decisions (legal status of sale to consumers and quality criteria), this results in four performance sub-tables to be filled with estimates. However, because swing-weighting simultaneously weighs each criterion’s importance and the relative magnitudes of effect of the alternatives, this requires all alternatives to be weighted simultaneously. Once alternatives are delineated into decisions and sub-alternatives, this is no longer possible.
Therefore, instead of calibrating the estimates using swing-weighting, global weighting is used (see also Monat, 2009). With global weighting, the metrics on which the alternatives effects on each criterion are estimated are established in advance. Specifically, in MDMCDA, the status quo represents a score of 0, and for each criterion, maximum deviation in the negative and positive directions are established. For example, if the status quo is relatively dismal, the positive extreme is set to 100, but the negative extreme to a smaller value, such as -20 (if things can get only around one fifth worse than they can get better). Another criterion may be scores from -100 to 50, if the status quo is already relatively desirable, but there is room for deterioration.
This approach fixes the scoring metrics such that scorers always have two anchor points (0 and either -100 or 100), and can score the estimates relative to those anchors. This eliminates the problem produced if a fixed scale would be used for all criteria (e.g. 0 to 100): in that case, the status quo is represented by a different score for each criterion, which introduces extraneous cognitive load for the scorers.
The magnitudes of the effect of the sub-alternative within each decision then manifest in the estimates scores. This has as second benefit that the weighting is restricted to the value one attaches to the criteria. In other words, this approach dissociates the more objective aspect of swing weighting fro its more subjective, moral aspect. That dissociation enables application of multiple weight profiles, enabling comparison of the effects of variations in criterion priority on total scores.
The terminology of MDMCDA is slightly different from the terminology of MCDA to retain unequivocal reference of ‘alternatives’ to the options comprising a decision. Therefore, in MDMCDA, each decision (e.g. legal status of sale to consumers) consists of two or more alternatives (avoiding the term “sub-alternatives”), and each specific configuration of alternatives (e.g. “prohibition”) is called a scenario. These scenarios, therefore, correspond to what in regular MCDA are the alternatives.
###-----------------------------------------------------------------------------
### Read criteria, estimates, weights, scenarios, and post-sets
###-----------------------------------------------------------------------------
criteria <-
mdmcda::read_criteria_from_xl(
criteriaFile,
showGraphs = FALSE);
estimates <-
mdmcda::read_performance_tables(input = scoredPST_path);
weights <-
mdmcda::read_weights_from_xl(input = weightsFile);
scenarioDefinitions <-
mdmcda::read_scenarioDefinitions_in_columns_from_xl(
scenariosFile
);
postsets <-
as.data.frame(openxlsx::read.xlsx(postSetsFile, sheet = 1));
###----------------------------------------------------------------------------
### Read labels
###----------------------------------------------------------------------------
### Read criterion labels
criterionLabels <-
mdmcda::read_criterionLabels_from_xl(
file.path(dataPath,
"mdmcda-data--criterionLabels_en.xlsx")
);
criterionLabels_NL <-
mdmcda::read_criterionLabels_from_xl(
file.path(dataPath,
"mdmcda-data--criterionLabels_nl.xlsx")
);
### Read decision labels
decisionLabels <-
mdmcda::read_decisionLabels_from_xl(
file.path(dataPath,
"mdmcda-data--decisionLabels_en.xlsx")
);
decisionLabels_NL <-
mdmcda::read_decisionLabels_from_xl(
file.path(dataPath,
"mdmcda-data--decisionLabels_nl.xlsx")
);
### Read decision descriptions
decisionDescriptions <-
mdmcda::read_decisionDescriptions_from_xl(
file.path(dataPath,
"mdmcda-data--decisionLabels_en.xlsx")
);
### Read scenario labels
scenarioLabels <-
mdmcda::read_scenarioLabels_from_xl(
file.path(dataPath,
"mdmcda-data--scenarioLabels_en.xlsx")
);
scenarioLabels_NL <-
mdmcda::read_scenarioLabels_from_xl(
file.path(dataPath,
"mdmcda-data--scenarioLabels_nl.xlsx")
);
### Read alternative labels
alternativeLabels <-
mdmcda::read_alternativeLabels_from_xl(
file.path(dataPath,
"mdmcda-data--alternativeLabels_en.xlsx")
);
alternativeLabels_NL <-
mdmcda::read_alternativeLabels_from_xl(
file.path(dataPath,
"mdmcda-data--alternativeLabels_nl.xlsx")
);
###-----------------------------------------------------------------------------
### Set orders for criteria, decisions, and scenarios
###-----------------------------------------------------------------------------
criterionOrder <-
setdiff(names(criterionLabels),
criteria$convenience$parentCriterionIds);
parentCriterionOrder <-
intersect(names(criterionLabels),
criteria$convenience$topCriterionClusters);
decisionOrder <- names(decisionLabels);
scenarioOrder <- names(scenarioLabels);
###-----------------------------------------------------------------------------
### Wrap the scenario labels for horizontal display
###-----------------------------------------------------------------------------
wrappedScenarioLabels <-
unlist(lapply(scenarioLabels, function(x)
paste(strwrap(x, 10), collapse="\n")
));
wrappedScenarioLabels_NL <-
unlist(lapply(scenarioLabels_NL, function(x)
paste(strwrap(x, 10), collapse="\n")
));
The criteria (‘outcomes’) have a hierarchical structure to facilitate weighting them efficiently. They are clustered based on domain, such that each outcome can be considered an indicator of the cluster outcome. For example, prevalence in the general population, prevalence in vulnerable populations, and frequency and intensity of use by MDMA users are all indicative of MDMA use (the overarching cluster). Therefore, if a decision maker values MDMA use as an outcome, that cluster can received a high weight. The relative contribution of the three indicators can then be finetuned by setting the weights of the individual outcomes. Similarly, a decision maker who does not want MDMA use to play a large role when determining their policy can set the cluster weight to a low value or to zero. The latter would immediately take all three contained outcomes out of the total scores computed for the scenarios (policy models).
In total, 2565 estimates were read. These estimates express estimated effects of 22 decisions (policy instruments), that together comprise a total of 95 alternatives (policy options), on a total of 27 criteria (outcomes).
In total, 48 post-sets were loaded, pertaining to 10 decisions (policy instruments) and 11 criteria (outcomes).
To set weights, all experts submitted individually determined weights for each outcome and each outcome cluster on a scale from 0-100, by first setting the weight of the most important cluster and the most important outcome in each cluster to 100, and then setting the weight of the other clusters and outcomes according to their relative importance compared to the most important cluster or outcome (e.g. an outcome half as important as the most important outcome in the same cluster would get a weight of 50). These individually set weights will later be used to compute consensus weights that will be used in the rest of the procedures.
Weights were loaded from 16 scorers with identifiers ‘Scorer3’, ‘Scorer4’, ‘Scorer5’, ‘Scorer6’, ‘Scorer7’, ‘Scorer8’, ‘Scorer9’, ‘Scorer10’, ‘Scorer11’, ‘Scorer12’, ‘Scorer13’, ‘Scorer14’, ‘Scorer15’, ‘Scorer16’, ‘Scorer17’ & ‘Scorer18’.
Scenarios are specific configurations of one selected alternative for each decision. The think-tank predefined 4 scenarios (policy models) with identifiers ‘repression’, ‘coffeeshop’, ‘adapted_coffeeshop’ & ‘free_market’.
Labels are read separately to enable easy translations to different languages.
In this section, the imported data are preprocessed. This can be inspected by expanding the code fragments.
Initially, the “protection of the environment” criterion did not have a parent. However, the experts did not weigh this criterion taking that into account, causing the resulting mean weight to be too high. To correct this, this criterion was placed into its own cluster with the weight defined as the mean weight of all other clusters.
In addition, the experts specified weights for the “policy aligns with conservative values” and “policy aligns with liberal values”, but the Think Tank results should be apolitical, and so we override these to zero here.
###-----------------------------------------------------------------------------
### The 'planet' parent for the 'environment' criterion was added
### later; so we need to add a weight for it. As weight, we take the
### mean weight of all clusters, as agreed in the think tank meeting
###-----------------------------------------------------------------------------
planetWeight <-
mean(
weights$allWeights$weight[
weights$allWeights$parentCriterion_id=="outcomes"
],
na.rm=TRUE
);
weights$individualWeights <-
lapply(weights$individualWeights,
function(dat) {
dat[dat$id=="planet", "weight"] <- planetWeight;
return(dat);
});
weights$allWeights[weights$allWeights$criterion_id=="planet", "weight"] <-
planetWeight;
###-----------------------------------------------------------------------------
### Set the weight of cultural values (liberal vs conservative) to 0 for the
### rest of the computations (because the think tank has no political/idealistic
### preference).
###-----------------------------------------------------------------------------
weights$allWeights[
weights$allWeights$criterion_id=="cultural_values", "weight"] <-
0;
Post-sets are individual estimates that were reconsidered by the think tank after the scoring days, or that were only completed after the scoring days.
### Do replacements
estimates$multiEstimateDf <-
mdmcda::set_postsets(
multiEstimateDf = estimates$multiEstimateDf,
postsets = postsets,
coder = scorerId
);
replacing estimate for the effect of alternative 2 for decision b2b_sale_legal_status on criterion costs_financial_crime, which was NA, with 5.
replacing estimate for the effect of alternative 3 for decision b2b_sale_legal_status on criterion costs_financial_crime, which was NA, with 5.
replacing estimate for the effect of alternative 4 for decision b2b_sale_legal_status on criterion costs_financial_crime, which was NA, with 5.
replacing estimate for the effect of alternative 5 for decision b2b_sale_legal_status on criterion costs_financial_crime, which was NA, with 15.
replacing estimate for the effect of alternative 2 for decision consumer_sale_legal_status on criterion state_revenues_vat, which was NA, with 80.
replacing estimate for the effect of alternative 3 for decision consumer_sale_legal_status on criterion state_revenues_vat, which was NA, with 100.
replacing estimate for the effect of alternative 4 for decision consumer_sale_legal_status on criterion state_revenues_vat, which was NA, with 60.
replacing estimate for the effect of alternative 2 for decision consumer_sale_legal_status on criterion state_revenues_tax, which was NA, with 80.
replacing estimate for the effect of alternative 3 for decision consumer_sale_legal_status on criterion state_revenues_tax, which was NA, with 100.
replacing estimate for the effect of alternative 4 for decision consumer_sale_legal_status on criterion state_revenues_tax, which was NA, with 60.
replacing estimate for the effect of alternative 1 for decision crime_priority on criterion criminalisation_of_users, which was NA, with 0.
replacing estimate for the effect of alternative 2 for decision crime_priority on criterion criminalisation_of_users, which was NA, with 0.
replacing estimate for the effect of alternative 3 for decision crime_priority on criterion criminalisation_of_users, which was NA, with -50.
replacing estimate for the effect of alternative 1 for decision crime_priority on criterion international_trafficking_mdma, which was NA, with 0.
replacing estimate for the effect of alternative 2 for decision crime_priority on criterion international_trafficking_mdma, which was NA, with 20.
replacing estimate for the effect of alternative 3 for decision crime_priority on criterion international_trafficking_mdma, which was NA, with 20.
replacing estimate for the effect of alternative 2 for decision international_strategy on criterion organized_crime_mdma, which was NA, with 0.
replacing estimate for the effect of alternative 3 for decision international_strategy on criterion organized_crime_mdma, which was NA, with 0.
replacing estimate for the effect of alternative 4 for decision international_strategy on criterion organized_crime_mdma, which was NA, with 0.
replacing estimate for the effect of alternative 5 for decision international_strategy on criterion organized_crime_mdma, which was NA, with 0.
replacing estimate for the effect of alternative 6 for decision international_strategy on criterion organized_crime_mdma, which was NA, with 0.
replacing estimate for the effect of alternative 2 for decision international_strategy on criterion organized_crime_other, which was NA, with 0.
replacing estimate for the effect of alternative 3 for decision international_strategy on criterion organized_crime_other, which was NA, with 0.
replacing estimate for the effect of alternative 4 for decision international_strategy on criterion organized_crime_other, which was NA, with 0.
replacing estimate for the effect of alternative 5 for decision international_strategy on criterion organized_crime_other, which was NA, with 0.
replacing estimate for the effect of alternative 6 for decision international_strategy on criterion organized_crime_other, which was NA, with 0.
replacing estimate for the effect of alternative 2 for decision international_strategy on criterion international_trafficking_mdma, which was NA, with 0.
replacing estimate for the effect of alternative 3 for decision international_strategy on criterion international_trafficking_mdma, which was NA, with 0.
replacing estimate for the effect of alternative 4 for decision international_strategy on criterion international_trafficking_mdma, which was NA, with 0.
replacing estimate for the effect of alternative 5 for decision international_strategy on criterion international_trafficking_mdma, which was NA, with 0.
replacing estimate for the effect of alternative 6 for decision international_strategy on criterion international_trafficking_mdma, which was NA, with 0.
replacing estimate for the effect of alternative 1 for decision legal_age_enforcing on criterion liberal_values, which was NA, with -25.
replacing estimate for the effect of alternative 1 for decision legal_age_enforcing on criterion conservative_values, which was NA, with -25.
replacing estimate for the effect of alternative 1 for decision licenses_for_selling on criterion organized_crime_mdma, which was NA, with -25.
replacing estimate for the effect of alternative 2 for decision licenses_for_selling on criterion organized_crime_mdma, which was NA, with 50.
replacing estimate for the effect of alternative 1 for decision licenses_for_selling on criterion organized_crime_other, which was NA, with 0.
replacing estimate for the effect of alternative 2 for decision licenses_for_selling on criterion organized_crime_other, which was NA, with 30.
replacing estimate for the effect of alternative 2 for decision ontneming on criterion criminalisation_of_users, which was NA, with 0.
replacing estimate for the effect of alternative 1 for decision pricing_restrictions on criterion international_image, which was NA, with 0.
replacing estimate for the effect of alternative 2 for decision pricing_restrictions on criterion international_image, which was NA, with 0.
replacing estimate for the effect of alternative 1 for decision production_legal_status on criterion small_crime_mdma, which was NA, with 0.
replacing estimate for the effect of alternative 2 for decision production_legal_status on criterion small_crime_mdma, which was NA, with 0.
replacing estimate for the effect of alternative 3 for decision production_legal_status on criterion small_crime_mdma, which was NA, with 0.
replacing estimate for the effect of alternative 4 for decision production_legal_status on criterion small_crime_mdma, which was NA, with 0.
replacing estimate for the effect of alternative 5 for decision production_legal_status on criterion small_crime_mdma, which was NA, with 0.
replacing estimate for the effect of alternative 1 for decision quality_management_sanctions on criterion international_image, which was NA, with 0.
replacing estimate for the effect of alternative 2 for decision quality_management_sanctions on criterion international_image, which was NA, with 0.
replacing estimate for the effect of alternative 3 for decision quality_management_sanctions on criterion international_image, which was NA, with 0.
### Also correct the parent element for environmental protection
estimates$mergedConfidences$parentCriterion_id <-
ifelse(estimates$mergedConfidences$parentCriterion_id == "outcomes",
"planet",
estimates$mergedConfidences$parentCriterion_id);
For decision (instrument) possession status, the alternative values (policy option values) were misspecified in the performance sub-tables: the values were ‘0’, ‘1’, ‘2’, ‘4’ & ‘5’ (3 was omitted). This code corrects this by shifting alternatives 4 and 5.
To verify this, the tables below were produced.
kableExtra::kable_styling(
knitr::kable(
table(
estimates$multiEstimateDf[
estimates$multiEstimateDf$decision_id=='posession_status',
c('alternative_label', 'alternative_value')]
)
)
);
0 | 1 | 2 | 4 | 5 | |
---|---|---|---|---|---|
Bezit is niet toestaan | 0 | 27 | 0 | 0 | 0 |
Bezit is toegestaan | 0 | 0 | 0 | 0 | 27 |
Gebruikershoeveelheid gedogen | 0 | 0 | 27 | 0 | 0 |
Gebruikershoeveelheid legaal, grootbezit gedoogd | 0 | 0 | 0 | 27 | 0 |
Niet van toepassing | 27 | 0 | 0 | 0 | 0 |
estimates$multiEstimateDf[
estimates$multiEstimateDf$decision_id=='posession_status',
'alternative_value'] <-
ifelse(
estimates$multiEstimateDf[
estimates$multiEstimateDf$decision_id=='posession_status',
'alternative_value'] < 3,
estimates$multiEstimateDf[
estimates$multiEstimateDf$decision_id=='posession_status',
'alternative_value'],
as.numeric(estimates$multiEstimateDf[
estimates$multiEstimateDf$decision_id=='posession_status',
'alternative_value']) - 1
);
cat("\n\nFrequencies of each option after correction:\n\n");
Frequencies of each option after correction:
kableExtra::kable_styling(
knitr::kable(
table(
estimates$multiEstimateDf[
estimates$multiEstimateDf$decision_id=='posession_status',
c('alternative_label', 'alternative_value')]
)
)
);
0 | 1 | 2 | 3 | 4 | |
---|---|---|---|---|---|
Bezit is niet toestaan | 0 | 27 | 0 | 0 | 0 |
Bezit is toegestaan | 0 | 0 | 0 | 0 | 27 |
Gebruikershoeveelheid gedogen | 0 | 0 | 27 | 0 | 0 |
Gebruikershoeveelheid legaal, grootbezit gedoogd | 0 | 0 | 0 | 27 | 0 |
Niet van toepassing | 27 | 0 | 0 | 0 | 0 |
The individual weights are now averaged, and then rescaled such that the most important outcome and cluster again had a weight of 100 (i.e. to the same metric used by the individual scorers). All outcome weights are then divided by 100 and multiplied with the weight of the corresponding clusters.
After this procedure, the most important outcome in each cluster has the weight of its cluster, and the other outcomes’ weights decrease proportionally. Finally, every weight is divided by the sum of all weights and multiplied by 100, so that every final weight expresses the relative contribution of the corresponding outcome in each model’s final scores.
Again, the visualisations can be inspected in the second tab.
###-----------------------------------------------------------------------------
### Aggregate weight estimates
###-----------------------------------------------------------------------------
weightsMeansAndSDs <- mdmcda::weightsMeansAndSDs(weights);
###-----------------------------------------------------------------------------
### Combine with criteria tree to accumulate over the hierachy. Note that
### because data.tree objects use R6, the criteria$criteriaTree object is
### updated in `criteria`, so we only need to store weightsMeansAndSDs
###-----------------------------------------------------------------------------
weightsMeansAndSDs <-
mdmcda::combine_weights_and_criteria(
weightsMeansAndSDs,
criteria,
weightCols = c(raw = 'weight_mean_proportion',
rescaled = 'weight_mean_rescaled_proportion')
);
###-----------------------------------------------------------------------------
### Compile weight profile
###-----------------------------------------------------------------------------
weightProfiles <-
mdmcda::create_weight_profile(weightsMeansAndSDs = weightsMeansAndSDs,
criteria = criteria,
profileName = weightProfileName);
weightProfileNames <- names(weightProfiles);
###-----------------------------------------------------------------------------
### Add weights and weighted estimates to multiEstimateDf
###-----------------------------------------------------------------------------
estimates$multiEstimateDf <-
mdmcda::weight_multiEstimateDf(
multiEstimateDf = estimates$multiEstimateDf,
weightProfiles = weightProfiles,
scorer = scorerId
);
### Remove the `scorerId` from the name of the weighted estimates because we
### didn't have multiple estimators (just the Think Tank estimates)
estimates$multiEstimateDf[, weightedEstimateName] <-
estimates$multiEstimateDf[, tempWeightedEstimateName];
###-----------------------------------------------------------------------------
### Export final average weights for use in Shiny app or other purposes
###-----------------------------------------------------------------------------
openxlsx::write.xlsx(
weightsMeansAndSDs,
file.path(workingPath,
"mdmcda-data--weightsMeansAndSDs.xlsx"),
overwrite = TRUE
);
### Note that the critera cluster weights are in column "rescaled_product"
### (criteria clusters can be recognized because their parent is the root
### element (the element with parentId "-"), in this case, "outcomes").
### The weights for the criteria themselves (i.e. the weights making up the
### weight profile we use in this analysis script) are in column
### "rescaled_total_percentage".
### Also export weight profiles directly
weightprofiles_asDf <-
mdmcda::write_weightProfile_to_xl(
weightProfiles,
file.path(
workingPath,
"mdmcda-data--weightProfiles.xlsx"
)
);
###-----------------------------------------------------------------------------
### Compute the total scores for each alternative in each decision
###-----------------------------------------------------------------------------
scores_per_alternative <-
mdmcda::compute_scores_per_alternative(
multiEstimateDf = estimates$multiEstimateDf,
weightProfiles = weightProfiles
);
###-----------------------------------------------------------------------------
### Compose best and worst scenario
###-----------------------------------------------------------------------------
bestAlternatives <-
mdmcda::compute_best_alternatives(
scores_per_alternative=scores_per_alternative,
ignoreRegex = "^0$"
);
worstAlternatives <-
mdmcda::compute_worst_alternatives(
scores_per_alternative=scores_per_alternative,
ignoreRegex = "^0$"
);
### From these data frames, extract the vectors to store in the object with
### scenario definitions. Sometimes, multiple options score the same. In these
### cases, select the first option for the scenario definition.
bestScenario <-
as.numeric(gsub("^.*\\s(\\d+)$",
"\\1",
bestAlternatives$alternative_id));
names(bestScenario) <- bestAlternatives$decision_id;
worstScenario <-
as.numeric(gsub("^.*\\s(\\d+)$",
"\\1",
worstAlternatives$alternative_id));
names(worstScenario) <- worstAlternatives$decision_id;
###-----------------------------------------------------------------------------
### Define scenario with tweaks to make it more acceptable to list of scenarios
###-----------------------------------------------------------------------------
xShopScenario <-
bestScenario;
xShopTweaks <-
c('posession_status' = 3,
### User quantity is legal, higher quantities condoned
'advertising' = 1,
### Advertising not allowed
'consumer_sale_legal_status' = 4,
### Analogous to pharmaceutical law
'legal_age' = 2,
### Age limit is 18 years
'export_status' = 1,
### Export is illegal
'healthpromotion_responsible_government' = 4
### Both governments
);
xShopScenario[names(xShopTweaks)] <-
xShopTweaks;
###-----------------------------------------------------------------------------
### Add these three new scenarios to the list of scenarios
###-----------------------------------------------------------------------------
scenarioDefinitions <-
c(scenarioDefinitions,
list(optimal_scenario = bestScenario,
worst_scenario = worstScenario,
x_shop = xShopScenario));
###-----------------------------------------------------------------------------
### Generate a weighted estimate dataframe with all scenarios and the selected
### alternatives
###-----------------------------------------------------------------------------
### Create dataframe for the weighted estimates
weightedEstimates <-
mdmcda::build_weighted_estimate_df(
multiEstimateDf = estimates$multiEstimateDf,
criterionOrder = criterionOrder,
decisionOrder = decisionOrder,
scenarioOrder = scenarioOrder,
scenarioDefinitions = scenarioDefinitions,
scorer = scorerId,
setMissingEstimates=0
);
### Actually weigh the estimates
weightedEstimates <-
mdmcda::weight_estimates_by_profile(weighted_estimate_df = weightedEstimates,
weight_profiles = weightProfiles);
### Add parent criterion identifiers
weightedEstimates$parentCriterion_id <-
criteria$convenience$parentCriterionIds_by_childId[
as.character(weightedEstimates$criterion_id)
];
###-----------------------------------------------------------------------------
### Total scores per scenario
###-----------------------------------------------------------------------------
scoresPerScenario <-
mdmcda::scores_by_scenario(weightedEstimates = weightedEstimates,
estimateCols = weightedEstimateName);
### Add labels
scoresPerScenario$label_en <-
scenarioLabels[scoresPerScenario$scenario_id];
scoresPerScenario$label_nl <-
scenarioLabels_NL[scoresPerScenario$scenario_id];
### Sort in scenarioOrder
scoresPerScenario <-
scoresPerScenario[match(scenarioOrder, scoresPerScenario$scenario_id), ];
### Get English and Dutch clean versions
scoresPerScenario_en <-
scoresPerScenario[, c("label_en", weightedEstimateName)];
scoresPerScenario_nl <-
scoresPerScenario[, c("label_nl", weightedEstimateName)];
### Round the scores
scoresPerScenario_en[, weightedEstimateName] <-
round(scoresPerScenario_en[, weightedEstimateName]);
scoresPerScenario_nl[, weightedEstimateName] <-
round(scoresPerScenario_nl[, weightedEstimateName]);
### Pretty column names
names(scoresPerScenario_en) <- c("Policy model", "Overall score");
names(scoresPerScenario_nl) <- c("Beleidsmodel", "Totaalscore");
###-----------------------------------------------------------------------------
### Compute the scores and plots for all scenarios
###-----------------------------------------------------------------------------
scenarioScores <-
lapply(
names(scenarioDefinitions),
function(x) {
return(
mdmcda::scenario_overview(
scenario = scenarioDefinitions[[x]],
scenarioLabel = scenarioLabels[x],
multiEstimateDf = estimates$multiEstimateDf,
estimateCol = weightedEstimateName,
decisionOrder = decisionOrder,
decisionLabels = decisionLabels,
criterionOrder = criterionOrder,
criterionLabels = criterionLabels,
alternativeLabels = alternativeLabels,
parentCriterionIds_by_childId =
criteria$convenience$parentCriterionIds_by_childId,
parentCriterionOrder = parentCriterionOrder,
scoreBarchart_criteria_args = list(yLab = "Total score per outcome\n(sum of weighted estimates)",
fill = "black"),
scoreBarchart_decisions_args = list(yLab = "Total score per instrument\n(sum of weighted estimates)",
fill = "black")
)
);
}
);
names(scenarioScores) <- names(scenarioDefinitions);
### Dutch versions
scenarioScores_nl <-
lapply(
names(scenarioDefinitions),
function(x) {
return(
mdmcda::scenario_overview(
scenario = scenarioDefinitions[[x]],
scenarioLabel = scenarioLabels_NL[x],
multiEstimateDf = estimates$multiEstimateDf,
estimateCol = weightedEstimateName,
decisionOrder = decisionOrder,
decisionLabels = decisionLabels_NL,
criterionOrder = criterionOrder,
criterionLabels = criterionLabels_NL,
alternativeLabels = alternativeLabels_NL,
parentCriterionIds_by_childId =
criteria$convenience$parentCriterionIds_by_childId,
parentCriterionOrder = parentCriterionOrder,
scoreBarchart_criteria_args = list(yLab = "Score",
fill = "white"),
scoreBarchart_decisions_args = list(yLab = "Score",
fill = "white")
)
);
}
);
names(scenarioScores_nl) <- names(scenarioDefinitions);
###~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
###
### Determine order for displaying the criteria within their clusters. This is
### based on the decreasingly sorted scores in the optimal model.
###
### This should not be deleted, but only needs to be run once and then the
### results are copy-pasted at the top.
###
###~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
# criteriaOrder <-
# unlist(
# lapply(
# parentCriterionOrder,
# function(clusterName) {
# res <-
# scenarioScores$optimal_scenario$byCriterion[
# criteria$convenience$childCriteriaIds[[clusterName]],
# ,
# drop=FALSE
# ];
# return(
# res$criterion_id[
# order(
# res[, weightedEstimateName],
# decreasing = TRUE
# )
# ]
# );
# }
# )
# );
# dput(criteriaOrder);
###~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
###
### End of commented out fragment that should be preserved
###
###~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
###-----------------------------------------------------------------------------
### Create performance tables for each scenario
###-----------------------------------------------------------------------------
performanceTables <-
lapply(
unique(weightedEstimates$scenario_id),
function(currentScenario) {
return(tidyr::pivot_wider(
weightedEstimates[weightedEstimates$scenario_id==currentScenario,
c("decision_id",
"criterion_id",
weightedEstimateName)],
id_cols="decision_id",
names_from="criterion_id",
values_from=tidyselect::all_of(weightedEstimateName)
));
}
);
names(performanceTables) <- unique(weightedEstimates$scenario_id);
cat("\n\n<div style='width: 70%'>\n\n");
cat(
mdmcda::plot_criteria(
criteria,
labels = criterionLabels,
show_weights = FALSE,
renderGraph = FALSE,
returnSVG = TRUE,
outputFile = file.path(workingPath,
"criteria-tree-without-weights.pdf")
)
);
cat("\n\n</div>\n\n");
for (currentCriterion in criterionOrder) {
ufs::cat0("\n\n##### ", criterionLabels[currentCriterion], "\n\n");
if (producePlots) {
ufs::knitAndSave(criteria$anchoringGraphs[[currentCriterion]],
path = workingPath,
figWidth = 5,
figHeight = 5,
figCaption = paste0("Outcome anchors for outcome ",
criterionLabels[currentCriterion]));
}
}
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning in sprintf(suffix, counter): one argument not used by format ''
Figure 1: Outcome anchors for outcome Use frequency and intensity by users.
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 2: Outcome anchors for outcome Use in vulnerable populations.
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 3: Outcome anchors for outcome Prevalence (general population).
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 4: Outcome anchors for outcome Quality of information about MDMA.
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 5: Outcome anchors for outcome Health damage.
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 6: Outcome anchors for outcome Stigmatization of users.
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 8: Outcome anchors for outcome Health benefits.
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 10: Outcome anchors for outcome Shift to other drugs.
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 12: Outcome anchors for outcome Criminalisation of users.
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 15: Outcome anchors for outcome Criminals exploitating vulnerable groups.
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 16: Outcome anchors for outcome International trafficking of MDMA.
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 17: Outcome anchors for outcome State revenue (other).
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 18: Outcome anchors for outcome State revenue (VAT).
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 22: Outcome anchors for outcome Economic boycotts.
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 23: Outcome anchors for outcome International image of the Netherlands.
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 24: Outcome anchors for outcome International legal countermeasures.
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 25: Outcome anchors for outcome Environmental damage.
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 26: Outcome anchors for outcome Policy consistent with conservative values.
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 27: Outcome anchors for outcome Policy consistent with liberal values.
These are the performance subtables that were scored. There is one for each combination of a policy instrument (with its various policy options) and outcome cluster (with its child outcomes).
performanceSubtables <-
mdmcda::all_performanceSubtables_from_estimates(
estimates = estimates,
criteria = criteria,
alternativeLabels = alternativeLabels,
parentCriterionOrder = parentCriterionOrder,
criterionLabels = criterionLabels,
decisionOrder = decisionOrder,
decisionLabels = decisionLabels,
humanReadableOnly = TRUE
);
for (parentCriterion_id in parentCriterionOrder) {
ufs::cat0("\n\n#### Outcome cluster: ", criterionLabels[parentCriterion_id], " {.tabset .tabset-pills}\n\n");
for (decision_id in decisionOrder) {
ufs::cat0("\n\n##### Instrument: ", decisionLabels[decision_id], "\n\n");
### Clear names of first two columns
names(performanceSubtables[[decision_id]][[parentCriterion_id]])[1:2] <-
"";
cat(
kableExtra::kable_styling(
knitr::kable(
performanceSubtables[[decision_id]][[parentCriterion_id]],
row.names=FALSE
)
)
);
}
}
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Possession | Not applicable | 0 | 0 | 0 |
Possession | Possession is illegal | 10 | 10 | 10 |
Possession | User quantity is condoned | 0 | 0 | 0 |
Possession | User quantity is legal, higher quantities condoned | -15 | -30 | -10 |
Possession | Possession is legal | -20 | -40 | -20 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Packaging | Not applicable | 0 | 0 | 0 |
Packaging | Plain packaging with prevention message | 5 | 5 | 5 |
Packaging | Only plain packaging | 0 | 0 | 0 |
Packaging | Only prevention message | -15 | -5 | 5 |
Packaging | No restrictions | -20 | -10 | -10 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Advertising | Not applicable | 0 | 0 | 0 |
Advertising | Advertising not allowed | 0 | 0 | 0 |
Advertising | Packaging advertising only | -5 | -10 | 0 |
Advertising | Age limited advertising only | -10 | -30 | -15 |
Advertising | Business to business advertising only | 0 | 0 | 0 |
Advertising | Advertising allowed | -20 | -30 | -15 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Sales across companies | Not applicable | 0 | 0 | 0 |
Sales across companies | Illegal | 0 | 0 | 0 |
Sales across companies | Regulated | 0 | 0 | 0 |
Sales across companies | Analogous to commodity law | 0 | 0 | 0 |
Sales across companies | Analogous to pharmaceutical law | 0 | 0 | 0 |
Sales across companies | Allowed | 0 | 0 | 0 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Sales to consumers | Not applicable | 0 | 0 | 0 |
Sales to consumers | Not allowed | 0 | 0 | 0 |
Sales to consumers | Regulated | 5 | -5 | 20 |
Sales to consumers | Analogous to commodity law | -10 | -20 | -20 |
Sales to consumers | Analogous to pharmaceutical law | 0 | 0 | 0 |
Sales to consumers | Allowed | -20 | -30 | -30 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Age limit | Not applicable | 0 | 0 | 0 |
Age limit | No age limit | -20 | 0 | 0 |
Age limit | Age limit is 18 years | 0 | 0 | 0 |
Age limit | Age limit is higher than 18 years | 0 | 0 | 0 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Punishable | Not applicable | 0 | 0 | 0 |
Punishable | Nobody punishable | -10 | 0 | 0 |
Punishable | Seller punishable | 20 | 0 | 0 |
Punishable | Seller and buyer punishable | 20 | 0 | 0 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Legal requirements for selling | Not applicable | 0 | 0 | 0 |
Legal requirements for selling | No license required | -25 | -20 | -20 |
Legal requirements for selling | License required | 25 | 0 | 20 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Price restrictions for consumer sale | Not applicable | 0 | 0 | 0 |
Price restrictions for consumer sale | No price restricions | -20 | -10 | -10 |
Price restrictions for consumer sale | Minimum pricing | 20 | 10 | 0 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
MDMA quality rules (QA) | Not applicable | 0 | 0 | 0 |
MDMA quality rules (QA) | No quality definition/requirements | 0 | 0 | 10 |
MDMA quality rules (QA) | Quality definition/requirements in place | -10 | -20 | 20 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Sanctioning QA rules | Not applicable | 0 | 0 | 0 |
Sanctioning QA rules | None | 0 | 0 | 0 |
Sanctioning QA rules | Mild | 0 | -10 | 10 |
Sanctioning QA rules | Severe | -10 | -20 | 20 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Monitoring | Not applicable | 0 | 0 | 0 |
Monitoring | None | 0 | 0 | 0 |
Monitoring | Selective | 0 | 0 | 0 |
Monitoring | Extensive | 0 | 0 | 20 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Health promotion (HP) funding | Not applicable | 0 | 0 | 0 |
Health promotion (HP) funding | No funding | -5 | -5 | -20 |
Health promotion (HP) funding | Minimal funding | 0 | 0 | 0 |
Health promotion (HP) funding | Substantial funding | 0 | 0 | 20 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Control prevention policy | Not applicable | 0 | 0 | 0 |
Control prevention policy | None | 0 | 0 | 0 |
Control prevention policy | Weak | 0 | 0 | 0 |
Control prevention policy | Strong | 0 | 0 | 0 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Health promotion perspective | Not applicable | 0 | 0 | 0 |
Health promotion perspective | Abstinence | 0 | 0 | -5 |
Health promotion perspective | Harm reduction | 5 | 0 | 20 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Government responsible for HP | Not applicable | 0 | 0 | 0 |
Government responsible for HP | No government | 0 | 0 | -10 |
Government responsible for HP | Regional government | 0 | 0 | 0 |
Government responsible for HP | National government | 0 | 0 | 0 |
Government responsible for HP | Both governments | 0 | 0 | 0 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Production of MDMA | Not applicable | 0 | 0 | 0 |
Production of MDMA | Illegal | 0 | 0 | 0 |
Production of MDMA | Regulated | -20 | -20 | 20 |
Production of MDMA | Analogous to commodity law | -40 | -40 | 20 |
Production of MDMA | Analogous to pharmaceutical law | 0 | 0 | 20 |
Production of MDMA | Allowed | -40 | -40 | 10 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Export status | Not applicable | 0 | 0 | 0 |
Export status | Export is illegal | 0 | 0 | 0 |
Export status | Export is legal | 0 | 0 | 0 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
International strategy | Not applicable | 0 | 0 | 0 |
International strategy | Compliant | 0 | 0 | 0 |
International strategy | Violation | 0 | 0 | 0 |
International strategy | Based on condoning | 0 | 0 | 0 |
International strategy | Inter se | 0 | 0 | 0 |
International strategy | Exceptional position | 0 | 0 | 0 |
International strategy | Adjustment of treaties | 0 | 0 | 0 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Priority crime fighting | Not applicable | 0 | 0 | 0 |
Priority crime fighting | Low | 0 | 0 | 0 |
Priority crime fighting | Selective | 0 | 0 | 0 |
Priority crime fighting | High | 0 | 10 | -10 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Maximum penalty | Not applicable | 0 | 0 | 0 |
Maximum penalty | Retain present sanction | 0 | 0 | 0 |
Maximum penalty | More severe sanction | 0 | 0 | 0 |
Use in vulnerable populations | Prevalence (general population) | Use frequency and intensity by users | ||
---|---|---|---|---|
Confiscation | Not applicable | 0 | 0 | 0 |
Confiscation | Unchanged | 0 | 0 | 0 |
Confiscation | Intensify | 0 | 0 | 0 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Possession | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Possession | Possession is illegal | -20 | -50 | 0 | -10 | -30 | 0 | -40 |
Possession | User quantity is condoned | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Possession | User quantity is legal, higher quantities condoned | -20 | 0 | 0 | 10 | 0 | 0 | 10 |
Possession | Possession is legal | -20 | 0 | 0 | 10 | 0 | 0 | 10 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Packaging | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Packaging | Plain packaging with prevention message | 5 | 0 | 0 | 0 | 0 | 50 | 0 |
Packaging | Only plain packaging | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Packaging | Only prevention message | -10 | -5 | 0 | 0 | 0 | 50 | 0 |
Packaging | No restrictions | -20 | -10 | 0 | 10 | 0 | 0 | 0 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Advertising | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Advertising | Advertising not allowed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Advertising | Packaging advertising only | -10 | -10 | 0 | 10 | 0 | 0 | 10 |
Advertising | Age limited advertising only | -30 | -30 | 0 | 30 | 0 | 0 | 40 |
Advertising | Business to business advertising only | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Advertising | Advertising allowed | -30 | -30 | 0 | 30 | 0 | 0 | 50 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Sales across companies | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sales across companies | Illegal | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sales across companies | Regulated | 10 | 0 | 0 | 0 | 0 | 10 | 10 |
Sales across companies | Analogous to commodity law | 10 | 0 | 0 | 0 | 0 | 10 | 10 |
Sales across companies | Analogous to pharmaceutical law | 20 | 0 | 0 | 0 | 0 | 20 | 10 |
Sales across companies | Allowed | 5 | 0 | 0 | 0 | 0 | 5 | 10 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Sales to consumers | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sales to consumers | Not allowed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sales to consumers | Regulated | -5 | -5 | 0 | 10 | 0 | 20 | 20 |
Sales to consumers | Analogous to commodity law | -20 | -20 | 0 | 20 | 0 | 10 | 30 |
Sales to consumers | Analogous to pharmaceutical law | 0 | 0 | 10 | 0 | 0 | 20 | 10 |
Sales to consumers | Allowed | -30 | -30 | 0 | 20 | 0 | 10 | 40 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Age limit | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Age limit | No age limit | -10 | -10 | 0 | 10 | 0 | 0 | 0 |
Age limit | Age limit is 18 years | 0 | 0 | 0 | 0 | -10 | 0 | -5 |
Age limit | Age limit is higher than 18 years | 0 | 0 | 0 | 0 | -20 | 0 | -10 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Punishable | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Punishable | Nobody punishable | -10 | -10 | 0 | 10 | 0 | 0 | 0 |
Punishable | Seller punishable | 10 | 10 | 0 | 0 | 0 | 0 | 0 |
Punishable | Seller and buyer punishable | 20 | -20 | 0 | 0 | -10 | 0 | -10 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Legal requirements for selling | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Legal requirements for selling | No license required | -15 | 0 | 0 | 0 | 0 | 0 | 0 |
Legal requirements for selling | License required | 20 | 10 | 0 | 0 | 0 | 40 | 0 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Price restrictions for consumer sale | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Price restrictions for consumer sale | No price restricions | -20 | -10 | 0 | 10 | 0 | 0 | 0 |
Price restrictions for consumer sale | Minimum pricing | 50 | 10 | 0 | -10 | -10 | 0 | 0 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
MDMA quality rules (QA) | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MDMA quality rules (QA) | No quality definition/requirements | 10 | 0 | 0 | 0 | 0 | 0 | 0 |
MDMA quality rules (QA) | Quality definition/requirements in place | 40 | 0 | 10 | 0 | 0 | 70 | 20 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Sanctioning QA rules | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sanctioning QA rules | None | 10 | 0 | -10 | 0 | 0 | 10 | 0 |
Sanctioning QA rules | Mild | 20 | 0 | 10 | 0 | 0 | 20 | 0 |
Sanctioning QA rules | Severe | 50 | 0 | 20 | 0 | 0 | 40 | 0 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Monitoring | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Monitoring | None | -30 | 0 | 0 | 0 | 0 | -50 | -20 |
Monitoring | Selective | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Monitoring | Extensive | 30 | 0 | 0 | 0 | 0 | 50 | 20 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Health promotion (HP) funding | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Health promotion (HP) funding | No funding | -30 | -5 | 0 | 0 | 0 | -50 | -20 |
Health promotion (HP) funding | Minimal funding | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Health promotion (HP) funding | Substantial funding | 30 | 15 | 5 | 15 | 0 | 50 | 20 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Control prevention policy | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Control prevention policy | None | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Control prevention policy | Weak | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Control prevention policy | Strong | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Health promotion perspective | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Health promotion perspective | Abstinence | -30 | -10 | -5 | -10 | -20 | -60 | -25 |
Health promotion perspective | Harm reduction | 15 | 10 | 5 | 10 | 0 | 10 | 10 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Government responsible for HP | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Government responsible for HP | No government | -10 | -10 | 0 | 0 | 0 | -20 | 0 |
Government responsible for HP | Regional government | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Government responsible for HP | National government | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Government responsible for HP | Both governments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Production of MDMA | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Production of MDMA | Illegal | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Production of MDMA | Regulated | -10 | 0 | 0 | 20 | 0 | 50 | 30 |
Production of MDMA | Analogous to commodity law | -20 | 0 | 0 | 10 | 0 | 50 | 30 |
Production of MDMA | Analogous to pharmaceutical law | 0 | 0 | 10 | 30 | 0 | 30 | 20 |
Production of MDMA | Allowed | -20 | 0 | 0 | 10 | 0 | 10 | 30 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Export status | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Export status | Export is illegal | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Export status | Export is legal | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
International strategy | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
International strategy | Compliant | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
International strategy | Violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
International strategy | Based on condoning | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
International strategy | Inter se | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
International strategy | Exceptional position | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
International strategy | Adjustment of treaties | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Priority crime fighting | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Priority crime fighting | Low | 10 | 10 | 0 | 5 | 0 | 5 | 10 |
Priority crime fighting | Selective | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Priority crime fighting | High | -20 | -15 | 0 | -5 | -20 | -40 | -40 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Maximum penalty | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Maximum penalty | Retain present sanction | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Maximum penalty | More severe sanction | 0 | -10 | 0 | 0 | 0 | 0 | 0 |
Health damage | Social damage | Health benefits | Social benefits | Shift to other drugs | Quality of information about MDMA | Stigmatization of users | ||
---|---|---|---|---|---|---|---|---|
Confiscation | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Confiscation | Unchanged | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Confiscation | Intensify | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Possession | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Possession | Possession is illegal | -100 | -100 | 0 | 0 | 0 | -50 |
Possession | User quantity is condoned | 0 | 0 | 0 | 0 | 0 | 0 |
Possession | User quantity is legal, higher quantities condoned | 50 | 50 | -20 | 0 | -30 | 20 |
Possession | Possession is legal | 50 | 50 | -20 | 0 | -30 | 20 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Packaging | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Packaging | Plain packaging with prevention message | 0 | 0 | -20 | 0 | 0 | 0 |
Packaging | Only plain packaging | 0 | 0 | -20 | 0 | 0 | 0 |
Packaging | Only prevention message | 0 | 0 | 0 | 0 | 0 | 0 |
Packaging | No restrictions | 0 | 0 | -20 | 0 | 0 | 0 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Advertising | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Advertising | Advertising not allowed | 0 | 0 | 0 | 0 | 0 | 0 |
Advertising | Packaging advertising only | 0 | 10 | 10 | 0 | 0 | 0 |
Advertising | Age limited advertising only | 0 | 30 | 30 | 0 | 0 | 0 |
Advertising | Business to business advertising only | 0 | 10 | 10 | 0 | 0 | 0 |
Advertising | Advertising allowed | 0 | 40 | 40 | 0 | 0 | 0 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Sales across companies | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Sales across companies | Illegal | 0 | 0 | 0 | 0 | 0 | 0 |
Sales across companies | Regulated | 0 | 0 | 60 | -10 | -10 | 0 |
Sales across companies | Analogous to commodity law | 0 | 0 | 80 | -10 | -80 | 0 |
Sales across companies | Analogous to pharmaceutical law | 0 | 0 | 60 | -10 | -10 | 0 |
Sales across companies | Allowed | 0 | 0 | 80 | -10 | -80 | 0 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Sales to consumers | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Sales to consumers | Not allowed | 0 | 0 | 0 | 0 | 0 | 0 |
Sales to consumers | Regulated | 50 | 40 | 20 | -20 | -10 | 30 |
Sales to consumers | Analogous to commodity law | 50 | 50 | 60 | -60 | -20 | 50 |
Sales to consumers | Analogous to pharmaceutical law | 50 | 40 | 20 | -20 | -10 | 30 |
Sales to consumers | Allowed | 50 | 50 | 60 | -60 | -20 | 50 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Age limit | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Age limit | No age limit | 50 | 50 | 10 | 0 | 0 | 0 |
Age limit | Age limit is 18 years | 30 | 30 | 10 | 0 | 0 | -10 |
Age limit | Age limit is higher than 18 years | 20 | 20 | 0 | 0 | 0 | -10 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Punishable | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Punishable | Nobody punishable | 50 | 50 | 30 | 0 | 0 | 20 |
Punishable | Seller punishable | 50 | 30 | 20 | 0 | 0 | 10 |
Punishable | Seller and buyer punishable | 30 | 10 | 10 | 0 | 0 | 10 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Legal requirements for selling | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Legal requirements for selling | No license required | 0 | 50 | -25 | 0 | 0 | 10 |
Legal requirements for selling | License required | 0 | 40 | 50 | 30 | 0 | 20 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Price restrictions for consumer sale | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Price restrictions for consumer sale | No price restricions | 0 | 0 | 0 | 0 | 0 | 0 |
Price restrictions for consumer sale | Minimum pricing | 0 | -20 | -10 | 0 | 0 | -10 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
MDMA quality rules (QA) | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
MDMA quality rules (QA) | No quality definition/requirements | 0 | 0 | 0 | 0 | 0 | 0 |
MDMA quality rules (QA) | Quality definition/requirements in place | 0 | 20 | 20 | -10 | 0 | 0 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Sanctioning QA rules | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Sanctioning QA rules | None | 0 | 0 | 0 | 0 | 0 | 0 |
Sanctioning QA rules | Mild | 0 | 0 | 0 | 0 | 0 | 0 |
Sanctioning QA rules | Severe | 0 | 0 | 0 | 0 | 0 | 0 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Monitoring | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Monitoring | None | 0 | 0 | 0 | 0 | 0 | 0 |
Monitoring | Selective | 0 | 10 | 10 | 10 | 10 | 10 |
Monitoring | Extensive | 0 | 20 | 20 | 20 | 20 | 20 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Health promotion (HP) funding | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Health promotion (HP) funding | No funding | 0 | 0 | 0 | 0 | 0 | 0 |
Health promotion (HP) funding | Minimal funding | 0 | 0 | 0 | 0 | 0 | 0 |
Health promotion (HP) funding | Substantial funding | 0 | 0 | 0 | 0 | 0 | 0 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Control prevention policy | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Control prevention policy | None | 0 | 0 | 0 | 0 | 0 | 0 |
Control prevention policy | Weak | 0 | 0 | 0 | 0 | 0 | 0 |
Control prevention policy | Strong | 0 | 0 | 0 | 0 | 0 | 0 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Health promotion perspective | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Health promotion perspective | Abstinence | 0 | 0 | 0 | 0 | 0 | 0 |
Health promotion perspective | Harm reduction | 15 | 0 | 0 | 0 | 0 | 0 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Government responsible for HP | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Government responsible for HP | No government | 0 | 0 | 0 | 0 | 0 | 0 |
Government responsible for HP | Regional government | 0 | 0 | 0 | 0 | 0 | 0 |
Government responsible for HP | National government | 0 | 0 | 0 | 0 | 0 | 0 |
Government responsible for HP | Both governments | 0 | 0 | 0 | 0 | 0 | 0 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Production of MDMA | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Production of MDMA | Illegal | 0 | 0 | 0 | 0 | 0 | 0 |
Production of MDMA | Regulated | 0 | 0 | 50 | -10 | -10 | -10 |
Production of MDMA | Analogous to commodity law | 0 | 0 | 90 | -50 | -80 | -10 |
Production of MDMA | Analogous to pharmaceutical law | 0 | 0 | 20 | -10 | -10 | 0 |
Production of MDMA | Allowed | 0 | 0 | 90 | -60 | -90 | -10 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Export status | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Export status | Export is illegal | 0 | 0 | 0 | 0 | 0 | 0 |
Export status | Export is legal | 0 | 0 | 50 | -20 | -40 | 0 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
International strategy | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
International strategy | Compliant | 0 | 0 | 0 | 0 | 0 | 0 |
International strategy | Violation | 0 | 0 | 0 | 0 | 0 | 0 |
International strategy | Based on condoning | 0 | 0 | 0 | 0 | 0 | 0 |
International strategy | Inter se | 0 | 0 | 0 | 0 | 0 | 0 |
International strategy | Exceptional position | 0 | 0 | 0 | 0 | 0 | 0 |
International strategy | Adjustment of treaties | 0 | 0 | 0 | 0 | 0 | 0 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Priority crime fighting | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Priority crime fighting | Low | 0 | -20 | -50 | 20 | 0 | 10 |
Priority crime fighting | Selective | 0 | 0 | 0 | 0 | 20 | 0 |
Priority crime fighting | High | -50 | -20 | 20 | -20 | 20 | -20 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Maximum penalty | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Maximum penalty | Retain present sanction | 0 | 0 | 0 | 0 | 0 | 0 |
Maximum penalty | More severe sanction | -20 | 25 | 10 | 0 | 20 | -20 |
Criminalisation of users | MDMA-related small crime | Organized crime (MDMA-related) | Organized crime (not MDMA-related) | International trafficking of MDMA | Criminals exploitating vulnerable groups | ||
---|---|---|---|---|---|---|---|
Confiscation | Not applicable | 0 | 0 | 0 | 0 | 0 | 0 |
Confiscation | Unchanged | 0 | 0 | 0 | 0 | 0 | 0 |
Confiscation | Intensify | 0 | 25 | 60 | 60 | 20 | -10 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Possession | Not applicable | 0 | 0 | 0 | 0 | 0 |
Possession | Possession is illegal | 0 | 0 | 0 | 0 | 0 |
Possession | User quantity is condoned | 0 | 0 | 0 | 0 | 0 |
Possession | User quantity is legal, higher quantities condoned | 0 | 0 | 0 | 0 | 10 |
Possession | Possession is legal | 0 | 0 | 0 | 0 | 10 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Packaging | Not applicable | 0 | 0 | 0 | 0 | 0 |
Packaging | Plain packaging with prevention message | 70 | 70 | 0 | -20 | 0 |
Packaging | Only plain packaging | 80 | 80 | 0 | -30 | 0 |
Packaging | Only prevention message | 90 | 90 | 0 | -40 | 0 |
Packaging | No restrictions | 100 | 100 | 0 | -50 | 0 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Advertising | Not applicable | 0 | 0 | 0 | 0 | 0 |
Advertising | Advertising not allowed | 0 | 0 | 0 | 0 | 0 |
Advertising | Packaging advertising only | 30 | 30 | 0 | -10 | 0 |
Advertising | Age limited advertising only | 60 | 60 | 0 | -20 | 0 |
Advertising | Business to business advertising only | 10 | 20 | 0 | 0 | 0 |
Advertising | Advertising allowed | 100 | 100 | 0 | -25 | 0 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Sales across companies | Not applicable | 0 | 0 | 0 | 0 | 0 |
Sales across companies | Illegal | 0 | 0 | 0 | 0 | 0 |
Sales across companies | Regulated | 10 | 75 | 60 | 0 | 5 |
Sales across companies | Analogous to commodity law | 10 | 100 | 60 | 0 | 5 |
Sales across companies | Analogous to pharmaceutical law | 10 | 50 | 80 | 0 | 5 |
Sales across companies | Allowed | 10 | 100 | 60 | 0 | 15 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Sales to consumers | Not applicable | 0 | 0 | 0 | 0 | 0 |
Sales to consumers | Not allowed | 0 | 0 | 0 | 0 | 0 |
Sales to consumers | Regulated | 80 | 80 | 0 | -20 | 0 |
Sales to consumers | Analogous to commodity law | 100 | 100 | 0 | -25 | 0 |
Sales to consumers | Analogous to pharmaceutical law | 60 | 60 | 0 | -15 | 0 |
Sales to consumers | Allowed | 100 | 100 | 0 | -25 | 0 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Age limit | Not applicable | 0 | 0 | 0 | 0 | 0 |
Age limit | No age limit | 100 | 0 | 0 | -30 | 0 |
Age limit | Age limit is 18 years | 90 | 0 | 0 | -20 | -10 |
Age limit | Age limit is higher than 18 years | 70 | 0 | 0 | -10 | -20 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Punishable | Not applicable | 0 | 0 | 0 | 0 | 0 |
Punishable | Nobody punishable | 0 | 0 | 0 | 0 | 0 |
Punishable | Seller punishable | -5 | 0 | 0 | 10 | -20 |
Punishable | Seller and buyer punishable | -5 | 0 | 0 | 10 | -20 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Legal requirements for selling | Not applicable | 0 | 0 | 0 | 0 | 0 |
Legal requirements for selling | No license required | 100 | 100 | 0 | -60 | 0 |
Legal requirements for selling | License required | 100 | 100 | 50 | -30 | -10 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Price restrictions for consumer sale | Not applicable | 0 | 0 | 0 | 0 | 0 |
Price restrictions for consumer sale | No price restricions | 100 | 100 | 0 | -40 | 0 |
Price restrictions for consumer sale | Minimum pricing | 70 | 70 | 0 | -20 | 0 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
MDMA quality rules (QA) | Not applicable | 0 | 0 | 0 | 0 | 0 |
MDMA quality rules (QA) | No quality definition/requirements | 0 | 0 | 0 | 0 | 0 |
MDMA quality rules (QA) | Quality definition/requirements in place | 0 | 0 | 0 | 30 | 20 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Sanctioning QA rules | Not applicable | 0 | 0 | 0 | 0 | 0 |
Sanctioning QA rules | None | 0 | 0 | 0 | -10 | 0 |
Sanctioning QA rules | Mild | 0 | 0 | 0 | 0 | -10 |
Sanctioning QA rules | Severe | 0 | 0 | 0 | 10 | -20 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Monitoring | Not applicable | 0 | 0 | 0 | 0 | 0 |
Monitoring | None | 0 | 0 | 0 | -20 | -20 |
Monitoring | Selective | 0 | 0 | 0 | 0 | 0 |
Monitoring | Extensive | 0 | 0 | 0 | 20 | 20 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Health promotion (HP) funding | Not applicable | 0 | 0 | 0 | 0 | 0 |
Health promotion (HP) funding | No funding | 0 | 0 | 0 | -50 | 0 |
Health promotion (HP) funding | Minimal funding | 0 | 0 | 0 | 0 | 0 |
Health promotion (HP) funding | Substantial funding | 0 | 0 | 0 | 30 | 0 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Control prevention policy | Not applicable | 0 | 0 | 0 | 0 | 0 |
Control prevention policy | None | 0 | 0 | 0 | 0 | 0 |
Control prevention policy | Weak | 0 | 0 | 0 | -10 | 0 |
Control prevention policy | Strong | 0 | 0 | 0 | -20 | 0 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Health promotion perspective | Not applicable | 0 | 0 | 0 | 0 | 0 |
Health promotion perspective | Abstinence | 0 | 0 | 0 | -20 | 0 |
Health promotion perspective | Harm reduction | 0 | 0 | 0 | 20 | 0 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Government responsible for HP | Not applicable | 0 | 0 | 0 | 0 | 0 |
Government responsible for HP | No government | 0 | 0 | 0 | -50 | 0 |
Government responsible for HP | Regional government | 0 | 0 | 0 | 0 | 0 |
Government responsible for HP | National government | 0 | 0 | 0 | 0 | 0 |
Government responsible for HP | Both governments | 0 | 0 | 0 | 0 | 0 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Production of MDMA | Not applicable | 0 | 0 | 0 | 0 | 0 |
Production of MDMA | Illegal | 0 | 0 | 0 | 0 | 0 |
Production of MDMA | Regulated | 10 | 90 | 70 | 30 | 70 |
Production of MDMA | Analogous to commodity law | 10 | 100 | 70 | 25 | 80 |
Production of MDMA | Analogous to pharmaceutical law | 10 | 80 | 80 | 35 | 60 |
Production of MDMA | Allowed | 10 | 100 | 70 | 0 | 100 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Export status | Not applicable | 0 | 0 | 0 | 0 | 0 |
Export status | Export is illegal | 0 | 0 | 0 | 0 | 0 |
Export status | Export is legal | 0 | 0 | 0 | 0 | 0 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
International strategy | Not applicable | 0 | 0 | 0 | 0 | 0 |
International strategy | Compliant | 0 | 0 | 0 | 0 | 0 |
International strategy | Violation | 0 | 0 | 0 | 0 | -10 |
International strategy | Based on condoning | 0 | 0 | 0 | 0 | 0 |
International strategy | Inter se | 0 | 0 | 0 | 0 | 10 |
International strategy | Exceptional position | 0 | 0 | 0 | 0 | -25 |
International strategy | Adjustment of treaties | 0 | 0 | 0 | 0 | 0 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Priority crime fighting | Not applicable | 0 | 0 | 0 | 0 | 0 |
Priority crime fighting | Low | 0 | 0 | 0 | 0 | 20 |
Priority crime fighting | Selective | 0 | 0 | 0 | 0 | 0 |
Priority crime fighting | High | 0 | 20 | 20 | -35 | -40 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Maximum penalty | Not applicable | 0 | 0 | 0 | 0 | 0 |
Maximum penalty | Retain present sanction | 0 | 0 | 0 | 0 | 0 |
Maximum penalty | More severe sanction | 0 | 10 | 0 | 0 | -20 |
State revenue (VAT) | State revenue (other) | Costs related to pollution (dumpings) | Costs related to health damage | Costs related to crime | ||
---|---|---|---|---|---|---|
Confiscation | Not applicable | 0 | 0 | 0 | 0 | 0 |
Confiscation | Unchanged | 0 | 0 | 0 | 0 | 0 |
Confiscation | Intensify | 0 | 100 | 0 | 0 | -80 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Possession | Not applicable | 0 | 0 | 0 |
Possession | Possession is illegal | 0 | 0 | 0 |
Possession | User quantity is condoned | -30 | 0 | 0 |
Possession | User quantity is legal, higher quantities condoned | -40 | -5 | -30 |
Possession | Possession is legal | -55 | -10 | -40 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Packaging | Not applicable | 0 | 0 | 0 |
Packaging | Plain packaging with prevention message | -5 | 0 | 0 |
Packaging | Only plain packaging | -10 | 0 | 0 |
Packaging | Only prevention message | -20 | 0 | 0 |
Packaging | No restrictions | -30 | 0 | 0 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Advertising | Not applicable | 0 | 0 | 0 |
Advertising | Advertising not allowed | 0 | 0 | 0 |
Advertising | Packaging advertising only | -20 | 0 | 0 |
Advertising | Age limited advertising only | -20 | 0 | 0 |
Advertising | Business to business advertising only | -20 | 0 | 0 |
Advertising | Advertising allowed | -30 | 0 | 0 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Sales across companies | Not applicable | 0 | 0 | 0 |
Sales across companies | Illegal | -10 | 0 | 0 |
Sales across companies | Regulated | 0 | 0 | 0 |
Sales across companies | Analogous to commodity law | -30 | 0 | 0 |
Sales across companies | Analogous to pharmaceutical law | -20 | 0 | 0 |
Sales across companies | Allowed | -30 | 0 | 0 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Sales to consumers | Not applicable | 0 | 0 | 0 |
Sales to consumers | Not allowed | 0 | 0 | 0 |
Sales to consumers | Regulated | -40 | 0 | -15 |
Sales to consumers | Analogous to commodity law | -60 | 0 | -15 |
Sales to consumers | Analogous to pharmaceutical law | -15 | 0 | 0 |
Sales to consumers | Allowed | -60 | 0 | -15 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Age limit | Not applicable | 0 | 0 | 0 |
Age limit | No age limit | 0 | 0 | 0 |
Age limit | Age limit is 18 years | 20 | 0 | 0 |
Age limit | Age limit is higher than 18 years | 20 | 0 | 0 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Punishable | Not applicable | 0 | 0 | 0 |
Punishable | Nobody punishable | 0 | 0 | 0 |
Punishable | Seller punishable | 10 | 0 | 0 |
Punishable | Seller and buyer punishable | 10 | 0 | 0 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Legal requirements for selling | Not applicable | 0 | 0 | 0 |
Legal requirements for selling | No license required | -80 | 0 | 0 |
Legal requirements for selling | License required | -50 | 0 | 0 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Price restrictions for consumer sale | Not applicable | 0 | 0 | 0 |
Price restrictions for consumer sale | No price restricions | 0 | 0 | 0 |
Price restrictions for consumer sale | Minimum pricing | 0 | 0 | 0 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
MDMA quality rules (QA) | Not applicable | 0 | 0 | 0 |
MDMA quality rules (QA) | No quality definition/requirements | 0 | 0 | 0 |
MDMA quality rules (QA) | Quality definition/requirements in place | 20 | 0 | 0 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Sanctioning QA rules | Not applicable | 0 | 0 | 0 |
Sanctioning QA rules | None | 0 | 0 | 0 |
Sanctioning QA rules | Mild | 0 | 0 | 0 |
Sanctioning QA rules | Severe | 0 | 0 | 0 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Monitoring | Not applicable | 0 | 0 | 0 |
Monitoring | None | 0 | 0 | 0 |
Monitoring | Selective | 10 | 0 | 0 |
Monitoring | Extensive | 20 | 0 | 0 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Health promotion (HP) funding | Not applicable | 0 | 0 | 0 |
Health promotion (HP) funding | No funding | -30 | 0 | 0 |
Health promotion (HP) funding | Minimal funding | -20 | 0 | 0 |
Health promotion (HP) funding | Substantial funding | 0 | 0 | 0 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Control prevention policy | Not applicable | 0 | 0 | 0 |
Control prevention policy | None | 0 | 0 | 0 |
Control prevention policy | Weak | 0 | 0 | 0 |
Control prevention policy | Strong | 0 | 0 | 0 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Health promotion perspective | Not applicable | 0 | 0 | 0 |
Health promotion perspective | Abstinence | 10 | 0 | 0 |
Health promotion perspective | Harm reduction | 0 | 0 | 0 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Government responsible for HP | Not applicable | 0 | 0 | 0 |
Government responsible for HP | No government | 0 | 0 | 0 |
Government responsible for HP | Regional government | 0 | 0 | 0 |
Government responsible for HP | National government | 0 | 0 | 0 |
Government responsible for HP | Both governments | -10 | 0 | 0 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Production of MDMA | Not applicable | 0 | 0 | 0 |
Production of MDMA | Illegal | 0 | 0 | 0 |
Production of MDMA | Regulated | -60 | 0 | -60 |
Production of MDMA | Analogous to commodity law | -90 | -10 | -90 |
Production of MDMA | Analogous to pharmaceutical law | -60 | 0 | -60 |
Production of MDMA | Allowed | -90 | -10 | -90 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Export status | Not applicable | 0 | 0 | 0 |
Export status | Export is illegal | 0 | 0 | 0 |
Export status | Export is legal | -90 | -10 | -90 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
International strategy | Not applicable | 0 | 0 | 0 |
International strategy | Compliant | 0 | 0 | 0 |
International strategy | Violation | -50 | 0 | -30 |
International strategy | Based on condoning | -40 | 0 | -10 |
International strategy | Inter se | -20 | 0 | 0 |
International strategy | Exceptional position | -40 | 0 | -30 |
International strategy | Adjustment of treaties | -50 | 0 | -30 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Priority crime fighting | Not applicable | 0 | 0 | 0 |
Priority crime fighting | Low | -50 | 0 | -20 |
Priority crime fighting | Selective | 0 | 0 | 0 |
Priority crime fighting | High | 20 | 0 | 0 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Maximum penalty | Not applicable | 0 | 0 | 0 |
Maximum penalty | Retain present sanction | 0 | 0 | 0 |
Maximum penalty | More severe sanction | 30 | 0 | 0 |
International image of the Netherlands | Economic boycotts | International legal countermeasures | ||
---|---|---|---|---|
Confiscation | Not applicable | 0 | 0 | 0 |
Confiscation | Unchanged | 0 | 0 | 0 |
Confiscation | Intensify | 30 | 0 | 0 |
Environmental damage | ||
---|---|---|
Possession | Not applicable | 0 |
Possession | Possession is illegal | 0 |
Possession | User quantity is condoned | 0 |
Possession | User quantity is legal, higher quantities condoned | 0 |
Possession | Possession is legal | 0 |
Environmental damage | ||
---|---|---|
Packaging | Not applicable | 0 |
Packaging | Plain packaging with prevention message | 20 |
Packaging | Only plain packaging | 10 |
Packaging | Only prevention message | 10 |
Packaging | No restrictions | -20 |
Environmental damage | ||
---|---|---|
Advertising | Not applicable | 0 |
Advertising | Advertising not allowed | 0 |
Advertising | Packaging advertising only | 0 |
Advertising | Age limited advertising only | 0 |
Advertising | Business to business advertising only | 0 |
Advertising | Advertising allowed | 0 |
Environmental damage | ||
---|---|---|
Sales across companies | Not applicable | 0 |
Sales across companies | Illegal | 0 |
Sales across companies | Regulated | 0 |
Sales across companies | Analogous to commodity law | 0 |
Sales across companies | Analogous to pharmaceutical law | 0 |
Sales across companies | Allowed | 0 |
Environmental damage | ||
---|---|---|
Sales to consumers | Not applicable | 0 |
Sales to consumers | Not allowed | 0 |
Sales to consumers | Regulated | 0 |
Sales to consumers | Analogous to commodity law | 0 |
Sales to consumers | Analogous to pharmaceutical law | 0 |
Sales to consumers | Allowed | 0 |
Environmental damage | ||
---|---|---|
Age limit | Not applicable | 0 |
Age limit | No age limit | 0 |
Age limit | Age limit is 18 years | 0 |
Age limit | Age limit is higher than 18 years | 0 |
Environmental damage | ||
---|---|---|
Punishable | Not applicable | 0 |
Punishable | Nobody punishable | 0 |
Punishable | Seller punishable | 0 |
Punishable | Seller and buyer punishable | 0 |
Environmental damage | ||
---|---|---|
Legal requirements for selling | Not applicable | 0 |
Legal requirements for selling | No license required | 0 |
Legal requirements for selling | License required | 0 |
Environmental damage | ||
---|---|---|
Price restrictions for consumer sale | Not applicable | 0 |
Price restrictions for consumer sale | No price restricions | 0 |
Price restrictions for consumer sale | Minimum pricing | 0 |
Environmental damage | ||
---|---|---|
MDMA quality rules (QA) | Not applicable | 0 |
MDMA quality rules (QA) | No quality definition/requirements | 0 |
MDMA quality rules (QA) | Quality definition/requirements in place | 50 |
Environmental damage | ||
---|---|---|
Sanctioning QA rules | Not applicable | 0 |
Sanctioning QA rules | None | -20 |
Sanctioning QA rules | Mild | 30 |
Sanctioning QA rules | Severe | 50 |
Environmental damage | ||
---|---|---|
Monitoring | Not applicable | 0 |
Monitoring | None | 0 |
Monitoring | Selective | 20 |
Monitoring | Extensive | 30 |
Environmental damage | ||
---|---|---|
Health promotion (HP) funding | Not applicable | 0 |
Health promotion (HP) funding | No funding | 0 |
Health promotion (HP) funding | Minimal funding | 0 |
Health promotion (HP) funding | Substantial funding | 0 |
Environmental damage | ||
---|---|---|
Control prevention policy | Not applicable | 0 |
Control prevention policy | None | 0 |
Control prevention policy | Weak | 0 |
Control prevention policy | Strong | 0 |
Environmental damage | ||
---|---|---|
Health promotion perspective | Not applicable | 0 |
Health promotion perspective | Abstinence | 10 |
Health promotion perspective | Harm reduction | 0 |
Environmental damage | ||
---|---|---|
Government responsible for HP | Not applicable | 0 |
Government responsible for HP | No government | 0 |
Government responsible for HP | Regional government | 0 |
Government responsible for HP | National government | 0 |
Government responsible for HP | Both governments | 0 |
Environmental damage | ||
---|---|---|
Production of MDMA | Not applicable | 0 |
Production of MDMA | Illegal | 0 |
Production of MDMA | Regulated | 20 |
Production of MDMA | Analogous to commodity law | 30 |
Production of MDMA | Analogous to pharmaceutical law | 50 |
Production of MDMA | Allowed | 10 |
Environmental damage | ||
---|---|---|
Export status | Not applicable | 0 |
Export status | Export is illegal | 0 |
Export status | Export is legal | 60 |
Environmental damage | ||
---|---|---|
International strategy | Not applicable | 0 |
International strategy | Compliant | 0 |
International strategy | Violation | 0 |
International strategy | Based on condoning | 0 |
International strategy | Inter se | 0 |
International strategy | Exceptional position | 0 |
International strategy | Adjustment of treaties | 0 |
Environmental damage | ||
---|---|---|
Priority crime fighting | Not applicable | 0 |
Priority crime fighting | Low | -20 |
Priority crime fighting | Selective | 0 |
Priority crime fighting | High | 20 |
Environmental damage | ||
---|---|---|
Maximum penalty | Not applicable | 0 |
Maximum penalty | Retain present sanction | 0 |
Maximum penalty | More severe sanction | 20 |
Environmental damage | ||
---|---|---|
Confiscation | Not applicable | 0 |
Confiscation | Unchanged | 0 |
Confiscation | Intensify | 30 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Possession | Not applicable | 0 | 0 |
Possession | Possession is illegal | -100 | 100 |
Possession | User quantity is condoned | 0 | -30 |
Possession | User quantity is legal, higher quantities condoned | 50 | -90 |
Possession | Possession is legal | 80 | -100 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Packaging | Not applicable | 0 | 0 |
Packaging | Plain packaging with prevention message | 50 | 40 |
Packaging | Only plain packaging | 30 | 0 |
Packaging | Only prevention message | 70 | -20 |
Packaging | No restrictions | -40 | -80 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Advertising | Not applicable | 0 | 0 |
Advertising | Advertising not allowed | -50 | 50 |
Advertising | Packaging advertising only | 20 | -20 |
Advertising | Age limited advertising only | 60 | -40 |
Advertising | Business to business advertising only | 10 | -10 |
Advertising | Advertising allowed | 50 | -50 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Sales across companies | Not applicable | 0 | 0 |
Sales across companies | Illegal | -50 | 50 |
Sales across companies | Regulated | 40 | 40 |
Sales across companies | Analogous to commodity law | 0 | -30 |
Sales across companies | Analogous to pharmaceutical law | -20 | 45 |
Sales across companies | Allowed | -10 | -50 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Sales to consumers | Not applicable | 0 | 0 |
Sales to consumers | Not allowed | -100 | 100 |
Sales to consumers | Regulated | 100 | -20 |
Sales to consumers | Analogous to commodity law | 50 | -80 |
Sales to consumers | Analogous to pharmaceutical law | -20 | 0 |
Sales to consumers | Allowed | -20 | -100 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Age limit | Not applicable | 0 | 0 |
Age limit | No age limit | -50 | -80 |
Age limit | Age limit is 18 years | 70 | 30 |
Age limit | Age limit is higher than 18 years | -50 | 80 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Punishable | Not applicable | 0 | 0 |
Punishable | Nobody punishable | -25 | -25 |
Punishable | Seller punishable | 70 | 50 |
Punishable | Seller and buyer punishable | -20 | 70 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Legal requirements for selling | Not applicable | 0 | 0 |
Legal requirements for selling | No license required | -30 | -100 |
Legal requirements for selling | License required | 70 | 70 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Price restrictions for consumer sale | Not applicable | 0 | 0 |
Price restrictions for consumer sale | No price restricions | -40 | -60 |
Price restrictions for consumer sale | Minimum pricing | 20 | 40 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
MDMA quality rules (QA) | Not applicable | 0 | 0 |
MDMA quality rules (QA) | No quality definition/requirements | -50 | -30 |
MDMA quality rules (QA) | Quality definition/requirements in place | 50 | 30 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Sanctioning QA rules | Not applicable | 0 | 0 |
Sanctioning QA rules | None | -50 | -80 |
Sanctioning QA rules | Mild | 20 | -20 |
Sanctioning QA rules | Severe | 50 | 60 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Monitoring | Not applicable | 0 | 0 |
Monitoring | None | -70 | -70 |
Monitoring | Selective | 40 | 70 |
Monitoring | Extensive | 70 | 40 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Health promotion (HP) funding | Not applicable | 0 | 0 |
Health promotion (HP) funding | No funding | -20 | 20 |
Health promotion (HP) funding | Minimal funding | 0 | 0 |
Health promotion (HP) funding | Substantial funding | 20 | -40 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Control prevention policy | Not applicable | 0 | 0 |
Control prevention policy | None | 20 | -20 |
Control prevention policy | Weak | -20 | 20 |
Control prevention policy | Strong | -50 | 50 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Health promotion perspective | Not applicable | 0 | 0 |
Health promotion perspective | Abstinence | -80 | 100 |
Health promotion perspective | Harm reduction | 80 | -50 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Government responsible for HP | Not applicable | 0 | 0 |
Government responsible for HP | No government | -100 | -100 |
Government responsible for HP | Regional government | 0 | 0 |
Government responsible for HP | National government | 0 | 0 |
Government responsible for HP | Both governments | 0 | 0 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Production of MDMA | Not applicable | 0 | 0 |
Production of MDMA | Illegal | -100 | 100 |
Production of MDMA | Regulated | 100 | 20 |
Production of MDMA | Analogous to commodity law | 60 | -80 |
Production of MDMA | Analogous to pharmaceutical law | 40 | 0 |
Production of MDMA | Allowed | -10 | -100 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Export status | Not applicable | 0 | 0 |
Export status | Export is illegal | -30 | 30 |
Export status | Export is legal | 30 | -30 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
International strategy | Not applicable | 0 | 0 |
International strategy | Compliant | -50 | 70 |
International strategy | Violation | 25 | -70 |
International strategy | Based on condoning | 40 | -50 |
International strategy | Inter se | 50 | -40 |
International strategy | Exceptional position | 60 | -50 |
International strategy | Adjustment of treaties | 70 | -60 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Priority crime fighting | Not applicable | 0 | 0 |
Priority crime fighting | Low | -20 | -60 |
Priority crime fighting | Selective | 50 | -40 |
Priority crime fighting | High | -40 | 80 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Maximum penalty | Not applicable | 0 | 0 |
Maximum penalty | Retain present sanction | 0 | 0 |
Maximum penalty | More severe sanction | -20 | 60 |
Policy consistent with liberal values | Policy consistent with conservative values | ||
---|---|---|---|
Confiscation | Not applicable | 0 | 0 |
Confiscation | Unchanged | 0 | 0 |
Confiscation | Intensify | 20 | 80 |
The think tank predefined a number of policy models.
for (scenario_id in c("coffeeshop",
"adapted_coffeeshop",
"free_market",
"repression")) {
cat("\n\n#### ", scenarioLabels[scenario_id], "\n\n");
cat(
mdmcda::scenario_alternative_table(
scenarioDefinition = scenarioDefinitions[[scenario_id]],
alternativeLabels = alternativeLabels,
decisionOrder = decisionOrder,
decisionLabels = decisionLabels
)
);
}
Decision | Alternative |
---|---|
Possession | User quantity is condoned |
Packaging | Plain packaging with prevention message |
Advertising | Advertising not allowed |
Sales across companies | Illegal |
Sales to consumers | Regulated |
Age limit | Age limit is 18 years |
Punishable | Nobody punishable |
Legal requirements for selling | License required |
Price restrictions for consumer sale | No price restricions |
MDMA quality rules (QA) | No quality definition/requirements |
Sanctioning QA rules | Not applicable |
Monitoring | Extensive |
Health promotion (HP) funding | Substantial funding |
Control prevention policy | Weak |
Health promotion perspective | Harm reduction |
Government responsible for HP | Both governments |
Production of MDMA | Illegal |
Export status | Export is illegal |
International strategy | Based on condoning |
Priority crime fighting | High |
Maximum penalty | Retain present sanction |
Confiscation | Unchanged |
Decision | Alternative |
---|---|
Possession | User quantity is condoned |
Packaging | Plain packaging with prevention message |
Advertising | Advertising not allowed |
Sales across companies | Regulated |
Sales to consumers | Analogous to pharmaceutical law |
Age limit | Age limit is 18 years |
Punishable | Nobody punishable |
Legal requirements for selling | License required |
Price restrictions for consumer sale | Minimum pricing |
MDMA quality rules (QA) | Quality definition/requirements in place |
Sanctioning QA rules | Mild |
Monitoring | Extensive |
Health promotion (HP) funding | Substantial funding |
Control prevention policy | None |
Health promotion perspective | Harm reduction |
Government responsible for HP | Both governments |
Production of MDMA | Analogous to pharmaceutical law |
Export status | Export is illegal |
International strategy | Based on condoning |
Priority crime fighting | High |
Maximum penalty | More severe sanction |
Confiscation | Intensify |
Decision | Alternative |
---|---|
Possession | Possession is legal |
Packaging | No restrictions |
Advertising | Advertising allowed |
Sales across companies | Allowed |
Sales to consumers | Allowed |
Age limit | Not applicable |
Punishable | Nobody punishable |
Legal requirements for selling | No license required |
Price restrictions for consumer sale | No price restricions |
MDMA quality rules (QA) | No quality definition/requirements |
Sanctioning QA rules | None |
Monitoring | None |
Health promotion (HP) funding | No funding |
Control prevention policy | Strong |
Health promotion perspective | Not applicable |
Government responsible for HP | No government |
Production of MDMA | Allowed |
Export status | Export is legal |
International strategy | Exceptional position |
Priority crime fighting | Selective |
Maximum penalty | Retain present sanction |
Confiscation | Unchanged |
Decision | Alternative |
---|---|
Possession | Possession is illegal |
Packaging | Not applicable |
Advertising | Advertising not allowed |
Sales across companies | Illegal |
Sales to consumers | Not applicable |
Age limit | Age limit is 18 years |
Punishable | Not applicable |
Legal requirements for selling | Not applicable |
Price restrictions for consumer sale | Not applicable |
MDMA quality rules (QA) | Not applicable |
Sanctioning QA rules | Not applicable |
Monitoring | Extensive |
Health promotion (HP) funding | No funding |
Control prevention policy | Strong |
Health promotion perspective | Abstinence |
Government responsible for HP | No government |
Production of MDMA | Illegal |
Export status | Export is illegal |
International strategy | Compliant |
Priority crime fighting | High |
Maximum penalty | More severe sanction |
Confiscation | Intensify |
cat("\n\n<div style='width: 70%'>\n\n");
cat(
mdmcda::plot_criteria(
criteria,
labels = criterionLabels,
renderGraph = FALSE,
returnSVG = TRUE,
outputFile = file.path(workingPath,
"criteria-tree-with-weights.pdf")
)
);
cat("\n\n</div>\n\n");
These three tabs contain the main results. Note that additional details are available in the “Additional visualisations” tab.
if (producePlots) {
mainResultsFigure <-
mdmcda::scoreBarchart_scenariosByCluster(
weightedEstimates = weightedEstimates,
estimateCol = weightedEstimateName,
parentCriterionOrder = parentCriterionOrder,
parentCriterionLabels = criterionLabels,
scenarioOrder = scenarioOrder,
scenarioLabels = wrappedScenarioLabels
### , sortByScore = TRUE ### Uncomment to sort by score
) +
ggplot2::labs(title = NULL,
x = NULL,
y = "Total score (sum of weighted estimates)") +
ggplot2::guides(fill = ggplot2::guide_legend(nrow = 2)) +
ggplot2::theme(
plot.margin = ggplot2::margin(l=.5, r=.5, t=0, b=.5, unit = "line"),
panel.grid.major.x = ggplot2::element_blank(),
panel.grid.minor.x = ggplot2::element_blank(),
panel.grid.major.y = ggplot2::element_line(size=.1, color="grey")
);
ufs::knitAndSave(mainResultsFigure,
path = workingPath,
figWidth = 10,
figHeight = 5,
dpi = 600,
figCaption = "Main results figure (English version)");
mainResultsFigure_NL <-
mdmcda::scoreBarchart_scenariosByCluster(
weightedEstimates = weightedEstimates,
estimateCol = weightedEstimateName,
parentCriterionOrder = parentCriterionOrder,
parentCriterionLabels = criterionLabels_NL,
scenarioOrder = scenarioOrder,
scenarioLabels = wrappedScenarioLabels_NL
### , sortByScore = TRUE ### Uncomment to sort by score
) +
ggplot2::labs(title = NULL,
x = NULL,
y = "Totaalscore (som van gewogen schattingen)") +
ggplot2::guides(fill = ggplot2::guide_legend(nrow = 2)) +
ggplot2::theme(
plot.margin = ggplot2::margin(l=.5, r=.5, t=0, b=.5, unit = "line"),
panel.grid.major.x = ggplot2::element_blank(),
panel.grid.minor.x = ggplot2::element_blank(),
panel.grid.major.y = ggplot2::element_line(size=.1, color="grey")
);
ufs::knitAndSave(mainResultsFigure_NL,
path = workingPath,
figWidth = 10,
figHeight = 5,
dpi = 600,
figCaption = "Main results figure (Dutch version)");
}
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning in sprintf(suffix, counter): one argument not used by format ''
Figure 28: Main results figure (English version).
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 29: Main results figure (Dutch version).
###-----------------------------------------------------------------------------
### Scores per cluster and per scenario
###-----------------------------------------------------------------------------
clusterScores <-
mdmcda::criteriaCluster_df(
weightedEstimates = weightedEstimates,
estimateCol = weightedEstimateName,
parentCriterionOrder = parentCriterionOrder,
parentCriterionLabels = criterionLabels_NL,
scenarioOrder = scenarioOrder,
scenarioLabels = scenarioLabels_NL
);
for (i in scenarioOrder) {
mdmcda::cat0("\n\n#### ", scenarioLabels_NL[i], "\n\n");
print(
kableExtra::kable_styling(
knitr::kable(
clusterScores[clusterScores$scenario_id==i,
c('cluster_label',
'meanWeights_weighted_estimate')],
row.names=FALSE,
col.names=c("Cluster", "Score")
)
)
);
}
Cluster | Score |
---|---|
Criminaliteit | 4222.3637 |
Ideologische waarden | 0.0000 |
Financiele kosten en baten | 1811.9481 |
Milieubescherming | 1373.6109 |
Internationale politiek | -554.8366 |
Gebruik (prevalentie & patronen) | 657.7565 |
Gezondheid van de gebruiker | 5758.9394 |
Cluster | Score |
---|---|
Criminaliteit | 3814.2134 |
Ideologische waarden | 0.0000 |
Financiele kosten en baten | 1617.5156 |
Milieubescherming | 1107.7508 |
Internationale politiek | -264.8586 |
Gebruik (prevalentie & patronen) | 699.6037 |
Gezondheid van de gebruiker | 5725.0663 |
Cluster | Score |
---|---|
Criminaliteit | 3384.9998 |
Ideologische waarden | 0.0000 |
Financiele kosten en baten | 1449.6162 |
Milieubescherming | 1107.7508 |
Internationale politiek | -200.3435 |
Gebruik (prevalentie & patronen) | 816.9417 |
Gezondheid van de gebruiker | 4161.7869 |
Cluster | Score |
---|---|
Criminaliteit | 2248.8003 |
Ideologische waarden | 0.0000 |
Financiele kosten en baten | 745.4951 |
Milieubescherming | 310.1702 |
Internationale politiek | -168.7658 |
Gebruik (prevalentie & patronen) | 551.5716 |
Gezondheid van de gebruiker | 1840.4343 |
Cluster | Score |
---|---|
Criminaliteit | 1852.9857 |
Ideologische waarden | 0.0000 |
Financiele kosten en baten | 956.0448 |
Milieubescherming | 132.9301 |
Internationale politiek | -1064.5670 |
Gebruik (prevalentie & patronen) | -2241.8658 |
Gezondheid van de gebruiker | -1879.1651 |
Cluster | Score |
---|---|
Criminaliteit | 245.836069 |
Ideologische waarden | 0.000000 |
Financiele kosten en baten | -496.170673 |
Milieubescherming | 487.410332 |
Internationale politiek | 87.493071 |
Gebruik (prevalentie & patronen) | 4.885243 |
Gezondheid van de gebruiker | -3107.784375 |
Cluster | Score |
---|---|
Criminaliteit | -1229.0828 |
Ideologische waarden | 0.0000 |
Financiele kosten en baten | 100.2161 |
Milieubescherming | 0.0000 |
Internationale politiek | -455.2087 |
Gebruik (prevalentie & patronen) | -949.5807 |
Gezondheid van de gebruiker | -4718.4598 |
if (producePlots) {
alternativePerformancePlots <- list();
for (currentDecision in decisionOrder) {
ufs::heading(decisionLabels[currentDecision],
" {.tabset .tabset-pills}",
headingLevel = 5);
alternativePerformancePlots[[currentDecision]] <- list();
for (currentAlternative in names(alternativeLabels[[currentDecision]])) {
ufs::heading(alternativeLabels[[currentDecision]][[currentAlternative]],
headingLevel = 6);
alternativePerformancePlots[[currentDecision]][[currentAlternative]] <-
mdmcda::scoreBarchart_criteria_for_singleDecision(
multiEstimateDf = estimates$multiEstimateDf,
estimateCol=weightedEstimateName,
decision_id=currentDecision,
alternative_value = currentAlternative,
criterionOrder = criterionOrder,
criterionLabels = criterionLabels,
parentCriterionOrder = parentCriterionOrder,
parentCriterionIds_by_childId = criteria$convenience$parentCriterionIds_by_childId,
decisionLabels = decisionLabels,
alternativeLabels = alternativeLabels
);
ufs::knitAndSave(
alternativePerformancePlots[[currentDecision]][[currentAlternative]] +
ggplot2::theme(
plot.margin = ggplot2::margin(l=4, r=1, t=1, b=1,
unit = "line")
),
path=workingPath,
figCaption = paste0(
"Performance for alternative ",
decisionLabels[currentDecision], ": ",
alternativeLabels[[currentDecision]][[currentAlternative]]
)
);
}
}
}
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning in sprintf(suffix, counter): one argument not used by format ''
Figure 30: Performance for alternative Possession: Not applicable.
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 31: Performance for alternative Possession: Possession is illegal.
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Figure 32: Performance for alternative Possession: User quantity is condoned.
Warning: Using ragg device as default. Ignoring `type` and `antialias` arguments
Warning: one argument not used by format ''
Social benefits
Figure 7: Outcome anchors for outcome Social benefits.